CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD

CICADA：AD/ADRD 药物重新定位的临床信息学和计算方法

• 批准号: 10490346
• 负责人: Yong Chen
• 金额: $ 75.43万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10490346
• 关键词: Accounting; Address; Age; Algorithms; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Artificial Intelligence; Behavioral; Brain; Brain Pathology; Cessation of life; Characteristics; Clinical; Clinical Informatics; Cognitive; Computer software; Computing Methodologies; Data; Databases; Dementia; Detection; Diabetes Mellitus; Dimensions; Drug Design; Drug Exposure; Drug Modelings; Elderly; Electronic Health Record; Environmental Exposure; Event; Exposure to; FDA approved; Functional disorder; Genetic; Genetic Diseases; Goals; Health; Health Sciences; Heterogeneity; Hybrids; Hyperlipidemia; Hypertension; Impaired cognition; Infusion procedures; Intervention; Investments; Knowledge; Link; Literature; Machine Learning; Medicine; Meta-Analysis; Methods; Modeling; Natural Language Processing; Neurodegenerative Disorders; Ontology; Outcome; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacy facility; Phase; Phase II/III Clinical Trial; Prevention; Procedures; Regression Analysis; Reproducibility; Research; Risk; Risk Factors; Safety; Scoring Method; Semantics; Signal Transduction; Statistical Methods; Technology; Testing; Texas; Universities; base; biobank; cognitive development; detection method; drug candidate; effective therapy; efficacy evaluation; follow-up; genetic risk factor; high dimensionality; individual patient; knowledge graph; mild cognitive impairment; multidimensional data; multimodal data; multimodality; multiple datasets; novel; novel therapeutics; physical inactivity; resilience; response; social; social health determinants; success

Project Summary This proposal seeks support for developing advanced clinical informatics and computational approaches for drug-repositioning for Alzheimer's disease (AD) and related dementias (ADRD). The proposed project directly addresses the areas of emphasis in PAR-20-156 to “develop computational methods such as artificial intelligence/machine learning to investigate new uses of FDA-approved drugs or candidate drugs from failed Phase II/Phase III clinical trials through analysis of multimodal data.” The overarching goals of this proposal are to develop novel clinical informatics and computational approaches for drug repositioning of AD/ADRD. Specifically, we will develop statistical methods and ontology technology to extract drug-repositioning signals from multidimensional data (e.g., pharmacy-linked genetic data and biobank data, historical trials, and EHR data). The proposed framework is novel because it integrates advanced statistical inference procedures with semantic technology for data-driven and reproducible drug repositioning for AD/ADRD. We have three aims: We have three specific aims: Aim 1: Develop signal detection methods using multi-modal data (pharmacy-linked genetic data, genetic and electronic health record (EHR) data, and BioBank data). Aim 2: Evaluate the efficacy and safety of candidate drugs via historical trials and EHR data. Aim 3: Develop novel semantic and natural language processing (NLP) methods for Knowledge Graph (KG) construction. The success of this project will lead to novel computational methods, KG, and software for facilitating drug repositioning for AD/ADRD based on multimodal data. If successful, the proposed method could identify novel drug repositioning signals and generate novel hypotheses for prevention and treatment intervention of treat AD/ADRD. Our project holds the promise of identifying novel drug repositioning signals. This project is novel for integrating evidence synthesis methods with signal detection methods using advanced multimodal modeling, and it is potentially transformative for advancing prevention and treatment for AD/ADRD.

项目摘要 该提案寻求对发展先进的临床信息学和计算机技术的支持 治疗阿尔茨海默病(AD)和相关痴呆(ADRD)的药物重新定位方法。 拟议的项目直接涉及PAR-20-156中的重点领域，即“开发 研究新用途的计算方法，如人工智能/机器学习 FDA批准的药物或未通过II/III期临床试验的候选药物 对多模式数据的分析。 这项提案的总体目标是开发新的临床信息学和 AD/ADRD药物重新定位的计算方法。具体来说，我们将发展 用于提取药物定位信号的统计方法和本体技术 多维数据(例如，与药房相关的基因数据和生物库数据，历史试验， 和EHR数据)。提出的框架是新颖的，因为它集成了先进的统计 基于语义技术的数据驱动可重复性药物推理程序 重新定位AD/ADRD。我们有三个目标： 我们有三个具体目标： 目标1：开发使用多模式数据的信号检测方法(与药房相关 遗传数据、遗传和电子健康记录(EHR)数据和生物库数据)。 目的2：通过历史试验和电子病历评价候选药物的疗效和安全性 数据。 目标3：开发新的语义和自然语言处理(NLP)方法 知识图(KG)构建。 该项目的成功将带来新的计算方法、KG和软件 促进基于多模式数据的AD/ADRD药物重新定位。如果成功，则 提出的方法可以识别新的药物重新定位信号并产生新的假设 对治疗AD/ADRD进行防治干预。我们的项目有希望 识别新的药物重新定位信号。该项目在综合证据方面具有新颖性。 综合方法和使用高级多模式建模的信号检测方法， 它对推进AD/ADRD的预防和治疗具有潜在的变革性。